

**COMMONWEALTH OF KENTUCKY  
CABINET FOR HEALTH AND FAMILY SERVICES  
DEPARTMENT FOR MEDICAID SERVICES  
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

NOTE: This special called meeting will be held virtually via Zoom webinar.

<https://magellanhealth.zoom.us/s/878927054>

**Dial: +1 312 626 6799 (US Toll) or +1 646 558 8656 (US Toll)**

**Zoom Webinar ID: 878 927 054 / Password: 370089**

Thursday, May 21, 2020

1:00 P.M. to 4:00 P.M.

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
  - a. Approval of Meeting Minutes
- IV. New Business**
  - a. New Products to Market to be reviewed as single products:
    - i. Akliel<sup>®</sup> (Acne Agents, Topical)
    - ii. Nayzilam<sup>®</sup> (Anticonvulsants)
    - iii. Nurtec<sup>™</sup> ODT (Antimigraine, Other)
    - iv. Reyvow<sup>™</sup> (Antimigraine, Other)
    - v. Ubrelvy<sup>™</sup> (Antimigraine, Other)
    - vi. Nourianz<sup>™</sup> (Antiparkinson's Agents)
    - vii. Wakix<sup>™</sup> (Stimulants and Related Agents)
  - b. New Products to Market to be reviewed along with their respective classes:
    - i. Reblozyl<sup>®</sup> (Erythropoiesis Stimulating Agents)
    - ii. Brukinsa<sup>™</sup> (Oncology, Oral – Hematologic Cancer)
    - iii. Ayvakit<sup>®</sup> (Oncology, Oral – Other)
    - iv. Tazverik<sup>®</sup> (Oncology, Oral – Other)
    - v. Xenleta<sup>™</sup> (Pleuromutulins)
- V. Clinical Criteria Review – to occur within their respective full class reviews.**
  - a. Descovy for Pre-Exposure Prophylaxis (PrEP)
  - b. Hepatitis C Agents: Direct-Acting Antivirals
- VI. Therapeutic Classes with Recommended Changes**
  - a. Analgesics, Narcotics Short
  - b. Antibiotics, GI
  - c. Antivirals, Oral
    - i. Antivirals: Herpes
    - ii. Antivirals: Influenza
  - d. Bone Resorption Suppression and Related Agents
  - e. Cephalosporins and Related Antibiotics
    - i. Antibiotics: Cephalosporins 1<sup>st</sup> Generation
    - ii. Antibiotics: Cephalosporins 2<sup>nd</sup> Generation

- iii. Antibiotics: Cephalosporins 3<sup>rd</sup> Generation
- f. Erythropoiesis Stimulating Proteins
- g. Glucagon Agents
- h. Glucocorticoids, Inhaled
- i. Hepatitis C Agents
  - i. Hepatitis C: Direct-Acting Antiviral Agents
  - ii. Hepatitis C: Interferons
  - iii. Hepatitis C: Ribavirins
- j. HIV/AIDS
- k. Hypoglycemics, Insulin and Related Agents
- l. Oncology, Oral – Breast
- m. Oncology, Oral – Hematologic
- n. Oncology, Oral – Other
- o. Oncology, Oral – Renal Cell
- p. Pleuromutins
- q. Thrombopoiesis Stimulating Proteins

**VII. Consent Agenda**

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

Absorbable Sulfonamides	Hypoglycemics, Meglitinides
Analgesics, Narcotics Long	Hypoglycemics, Metformins
Androgenic Agents	Hypoglycemics, SGLT2
Antibiotics, Inhaled	Hypoglycemics, Sulfonylureas
Antibiotics, Vaginal	Hypoglycemics, Thiazolidinediones (TZD)
Antifungals, Oral	Intranasal Rhinitis Agents
Antihistamines, Minimally Sedating	Leukotriene Modifiers
Antihyperuricemics	Macrolides
Antineoplastic Agents, Topical	NSAIDs
Bronchodilators, Beta Agonist	Oncology, Oral – Lung
Colony Stimulating Factors	Oncology, Oral – Prostate
COPD Agents	Oncology, Oral – Skin
Epinephrine, Self-Injected	Opiate Dependence Treatments
Fluoroquinolones, Oral	Oxazolidinediones
Glucocorticoids, Oral	Pancreatic Enzymes
Growth Hormone	Penicillins
Hepatitis B Agents	Phosphate Binders
Hypoglycemics, Alpha-Glucosidase Inhibitors	Progestins for Cachexia
Hypoglycemics, Incretin Mimetics/Enhancers	Tetracyclines

**VIII. Adjournment**

- a. Schedule of Upcoming Meetings
  - i. **September 17, 2020**
  - ii. **November 19, 2020**
- b. Collection of Travel Vouchers

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.